Hereditary angioedema (HAE) is a rare autosomal dominantly inherited disease characterized by recurrent, self-limiting episodes of acute tissue swelling. Management of HAE in the past was often limited to symptom alleviation by means of painkillers and administration of fresh frozen plasma. The situation changed radically with the implementation of new disease-specific therapies whose efficacy has been confirmed in clinical trials. Targeted therapies include recombinant human plasma C1 inhibitor as well as kallikrein-kinin system modulators, namely ecallantide and icatibant. The latter is the latest therapeutic option available for HAE patients in Poland. It disrupts bradykinin pathway by blocking BK2 receptors. The aim of this review is to update the practicing allergologists and other health care providers on new advances in treatment of acute attacks of HAE.